Embattled Theranos chief executive Elizabeth Holmes took the stage at the Wall Street Journal’s WSJDLive conference to answer questions the publication raised about her blood-testing startup.
The Palo Alto company set out to revolutionize the blood-testing industry with a technology it claims could perform some 240 tests, ranging from cholesterol to cancer, from a tiny vial of blood. Investors poured $400 million into the startup, giving it a $9 billion valuation.
A recent Journal investigation challenged those claims, reporting that Theranos’s own lab equipment was handling only a fraction of the tests it sold to consumers. Sources also questioned the accuracy of the results.
Theranos has subsequently stopped collecting blood samples for all but one of its tests as U.S. Food and Drug Administration officials conducted an inspection of its facility and the Centers for Medicare and Medicaid Services, the main regulator of clinical labs, conducted an audit.
Here’s the archive of our liveblog:
This article originally appeared on Recode.net.